Sumitomo Pharma Co., Ltd. clinical trials

Also known as Sumitomo Dainippon Pharma.

Part of Sumitomo Chemical Co., Ltd., which holds 51.76% as of 2026-03-31. Source

The registry lists 273 studies whose lead sponsor is Sumitomo Pharma Co., Ltd. or one of 8 companies grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 273. Browse all 273 →

• A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's DiseaseRecruitingNCT06753331Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• SMP-3124LP in Adults With Advanced Solid TumorsRecruitingNCT06526819Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingNCT04176198Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICRecruitingNCT05491525Phase 2/3

  Sponsor listed in the registry: Urovant Sciences GmbH · First submitted after Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaRecruitingNCT06891885Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingNCT04988555Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Congenital Athymia Patient RegistryRecruitingNCT05329935

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted after Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their OffspringRecruitingNCT05739123

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted after Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisRecruitingNCT05862272Phase 3

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted after Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood CancersCompletedNCT07444268Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of DSP-0390 in Patients With Recurrent High-Grade GliomaActive, not recruitingNCT05023551Early Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXCompletedNCT05467176

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateCompletedNCT05605964Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for PregnancyCompletedNCT04756037Phase 3

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted after Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LPCompletedNCT06460064Phase 1
• TP-3654 Food Effect StudyCompletedNCT07492355Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)Active, not recruitingNCT06517940

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerCompletedNCT04666129Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination TherapyActive, not recruitingNCT05739136

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted after Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)CompletedNCT04712669Phase 2

  Sponsor listed in the registry: Altavant Sciences GmbH · First submitted after Altavant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• Phase 1 Study of Oral TP-1454CompletedNCT04328740Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanTerminatedNCT05359081Phase 3
• A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.CompletedNCT06037668Not applicable

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).TerminatedNCT05227209Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Thymus Transplantation Safety-EfficacyCompletedNCT01220531Not applicable

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted before Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• Expanded Access Protocol Thymus TransplantationCompletedNCT02274662Phase 4

  Sponsor listed in the registry: Sumitomo Pharma Switzerland GmbH · First submitted before Sumitomo Pharma Switzerland GmbH became part of Sumitomo Pharma Co., Ltd.

• Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)CompletedNCT05067478

  Sponsor listed in the registry: Urovant Sciences GmbH · First submitted after Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.TerminatedNCT05169710Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654CompletedNCT06389955Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid TumorsTerminatedNCT03604783Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic HyperplasiaCompletedNCT04103450Phase 3

  Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)CompletedNCT03902080Phase 3

  Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT03751124Phase 3

  Sponsor listed in the registry: Myovant Sciences GmbH · First submitted before Myovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic ProfileTerminatedNCT03416335Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT03412890Phase 3

  Sponsor listed in the registry: Myovant Sciences GmbH · First submitted before Myovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.

• The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From OlanzapineTerminatedNCT05213143Phase 4

  Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.

• Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia PatientsTerminatedNCT03784222Phase 4

  Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.

• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With SchizophreniaCompletedNCT05011669Phase 4

  Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.

• The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia PatientsCompletedNCT04432688

  Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.

• A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension PhaseTerminatedNCT04825860Phase 2/3
• Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseCompletedNCT02542696Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerCompletedNCT02231723Phase 1

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaCompletedNCT02993731Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT02753127Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesCompletedNCT01325441Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed GlioblastomaCompletedNCT02315534Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaCompletedNCT02279719Phase 1/2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 ElevationTerminatedNCT02432690Phase 2

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.

• A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial TherapyCompletedNCT03149003Phase 3

  Sponsor listed in the registry: Sumitomo Pharma America, Inc. · First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd.